Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares

Syndax Pharmaceuticals Inc

Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.
Annual base salary of $495,000 with target bonus of 40% and option grant for 220,000 shares.
Sabus previously CCO at Turning Point Therapeutics and 15-year Astellas veteran.
Role focuses on commercial strategy for potential 2024 launches of revumenib and axatilimab.
Severance includes 9-month base salary on termination w/o cause or good reason; 12-month + full vesting on change in control.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steve Sabus

Chief Commercial Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-12-05
Filed: December 5, 2022, 6:59 PM ET

On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Sabus was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-22-026017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.